PKI - PerkinElmer, Inc.
NYSE - NYSE Delayed price. Currency in USD
94.39
-1.46 (-1.52%)
At close: 4:04PM EST
94.78 +0.39 (0.41%)
After hours: 4:26PM EST
Stock chart is not supported by your current browser
| Previous close | 95.85 |
| Open | 95.89 |
| Bid | 25.96 x 800 |
| Ask | 94.48 x 1000 |
| Day's range | 94.18 - 96.17 |
| 52-week range | 71.83 - 103.00 |
| Volume | 564,466 |
| Avg. volume | 642,634 |
| Market cap | 10B |
| Beta (5Y Monthly) | 1.30 |
| PE ratio (TTM) | 44.99 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.28 (0.29%) |
| Ex-dividend date | 2020-01-16 |
| 1y target est | N/A |
- Business Wire
PerkinElmer Launches First FDA-Approved Assay Kit to Screen for Duchenne Muscular Dystrophy in Newborns
PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).
- GlobeNewswire
New Research: Key Drivers of Growth for Twenty-First Century Fox, Royal Gold, NIC, PerkinElmer, Chimera Investment, and CorEnergy Infrastructure Trust — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.